Ведение взрослых пациентов с сольтеряющей формой врожденной дисфункции коры надпочечников

На примере описанного в статье клинического случая показаны особенности течения врожденной дисфункции коры надпочечников (ВДКН) у взрослых больных с сольтеряющей формой заболевания. Представленный случай доказывает необходимость динамического наблюдения за взрослыми пациентами с ВДКН, что позволит избежать осложнений, которые могут возникать при неадекватном ведении.

врожденная дисфункция коры надпочечников у взрослых, глюкокортикоидная терапия, клинический случай

1. Merke D.P., Cutler G.B. New ideas for medical treatment of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30: 121-135.

2. Merke D.P., Bornstein S.R., Avila N.A., Chrousos G.P. NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 2002; 136: 320-334.

3. Speiser P.W., White P.C. Congenital adrenal hyperplasia. N Engl J Med 2003; 349: 776-788.

4. White P.C., Speiser P.W. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21: 245-291.

5. Merke D.P., Bornstein S.R. Congenital adrenal hyperplasia. Lancet 2005; 365: 2125-2136.

6. Bachelot A., Chakthoura Z., Rouxel A. et al. Classical Forms of Congenital Adrenal Hyperplasia due to 21-Hydroxilase Deficiency in Adults. Horm Res 2008; 69: 203-211.

7. Bode H.H., Cowley D.M. et al. Home monitoring of 17-OHP levels in congenital adrenal hyperplasia. Journal of Pediatrics 1999; 134: 185-189.

8. Rosler A. The natural history of salt-wasting disorders of adrenal and renal origin. J Clin Endocrinol Metab 1984; 59: 689-700.

9. Merke D.P. Approach to the Adult with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. J Clin Endocrinol Metab 2008; 93: 3: 653-660.

10. Speiser P.W., Azziz R., Baskin L.S. et al. A Summary of the Endocrine Society Clinical Practice Guidelines on Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency. Int J Pediatr Endocrinol 2010; 30.

11. Newell-Price J., Whiteman M., Rostami-Hodjegan A. et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) 2008; 68: 130-135.

12. Charmandari E., Matthews D.R., Johnston A. et al. Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory? J Clin Endocrinol Metab 2001; 86: 4679-4685.

13. Rosenfield R.L. Serum cortisol and 17-hydroxyprogesterone concentrations in children with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2002; 87: 2993.

14. Bachelot A., Chakhtoura Z., Samara-Boustani D. et al. Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency. Int J Pediatr Endocrinol 2010; 10: 326-275.